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ABSTRACT 
 
Aim 
To identify effective treatments and risk factors associated with death rattle in adults at the 
end of life. 
 
Background  
The presence of noisy, pooled respiratory tract secretions is among the most common 
symptoms in dying patients around the world. It is unknown if ‘death rattle’ distresses 
patients, but it can distress relatives and clinicians. Treatments appear unsatisfactory, so 
prophylaxis would be ideal if possible.  
 
Design 
Quantitative systematic review and narrative summary following Cochrane Collaboration 
guidelines. 
 
Data sources  
CINAHL, MEDLINE, Health Source Nursing and Web of Science were searched for 
international literature in any language published from 1993 - 2016 using MeSH headings 
and iterative interchangeable terms for ‘death rattle’. 
 
Review Methods 
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Randomised controlled trials were appraised using the Cochrane Collaboration’s tool for 
assessing risk of bias. Non-randomised studies were assessed using ROBINS-I tool for 
assessing risk of bias in non-randomised studies of interventions. Instances of treatment and 
risk were extracted and relevant key findings extracted in line with Cochrane methods. 
 
Results 
Five randomised trials and 23 non-randomised studies were analysed. No pharmacological or 
non-pharmacological treatment was found superior to placebo. There was a weak association 
between lung or brain metastases and presence of death rattle, but otherwise inconsistent 
empirical support for a range of potential risk factors.  
 
Conclusions 
Clinicians have no clear evidence to follow in either treating death rattle or preventing it 
occurring. However, several risk factors look promising candidates for prospective analysis, 
so this review concludes with clear recommendations for further research. 
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Summary statement 
Why is this review needed? 
 
• A Cochrane review from 2008 (last reviewed in 2017) focused solely on randomised 
control trials regarding evidence for pharmacological treatment of death rattle and did 
not examine risk factors or alternative treatments. 
• Treatment of death rattle with antimuscarinic medication appears unsatisfactory and a 
further review of the literature might uncover different or new pharmacological or 
non-pharmacological treatments. 
• The identification of risk factors associated with death rattle development would 
allow for consideration of prophylactic treatment. 
 
What are the key findings? 
 
• No new approaches to pharmacological treatment were found and no published 
research was discovered concerning effective non-pharmacological treatments and 
nursing interventions. 
• There was a weak but consistent association between brain and/or lung metastases and 
development of death rattle 
• There was no consensus regarding manageable risk factors associated with death 
rattle development in the literature. 
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How should the findings be used to influence policy/practice/research/education 
 
• Research is needed to identify risk factors pertaining to death rattle to enable 
prophylactic treatment. 
• Research is needed to determine whether specific techniques for the nursing 
management of death rattle, such as suctioning and positional changes influence 
outcomes. 
• Research is needed to ascertain whether anti-muscarinic medication is the correct 
treatment for death rattle, as research has not shown that it is superior to placebo. 
 
Keywords 
death rattle, respiratory tract secretions, bronchial secretions, palliative care, terminal care, 
end-of-life care, cholinergic antagonists, nurses/midwives/nursing, literature review, 
systematic review. 
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INTRODUCTION 
Noisy respiratory tract secretions at the end of life are commonly called ‘death rattle’ (Wee et 
al., 2006a). Death rattle and its associated distress, is experienced around the world. The 
international literature reports a wide-ranging prevalence from 12-80% (Hugel et al., 2006; 
Pace et al., 2009). Death rattle is one of the most common symptoms in dying patients 
alongside pain, nausea, dyspnoea and agitation (Gambles et al., 2009). It is generally treated 
with antimuscarinic medication alongside repositioning of the patient for postural drainage 
and oropharyngeal suctioning if appropriate (Hughes et al., 2000). In addition, explanations 
should be offered to family and friends witnessing death rattle to alleviate distress (Hirsch et 
al., 2012). However, efficacy of both pharmacological and non-pharmacological treatments 
can be inconsistent for patients and the outcome is often perceived as unsatisfying for 
clinicians and relatives alike (Fielding & Long, 2014). 
 
Background 
The Oxford Textbook of Palliative Medicine describes death rattle in the following manner: 
‘Inability to clear secretion from the oropharynx and trachea often results in noisy ('rattling') 
respiration as the secretions oscillate up and down in conjunction with expiration and 
inspiration’(Twycross & Lichter, 1999, p.985). 
 
The aetiology of death rattle is disputed. Observing that drug treatments vary in efficacy, 
Bennett (1996) and Wildiers and Menten (2002) concluded that there must be two types of 
death rattle, calling them Type 1 and 2, or real and pseudo death rattle respectively. They 
proposed the first type to be a result of retained upper respiratory tract secretions which 
responds well to treatment with antimuscarinic medication. The second type responds poorly 
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to antimuscarinic treatment because it is considered to be a result of accumulated bronchial 
secretions secondary to infection or pulmonary disease. Neither Bennett (1996) nor Wildiers 
and Menten (2002) produced any evidence to support their claims. Nevertheless, the idea that 
there are two types of death rattle was supported by Morita et al. (2004b). They agreed that if 
the patient's inability to expectorate (Type 1) caused death rattle, antimuscarinic drugs were 
expected to be effective, while a different approach would be required in the treatment for 
Type 2 death rattle. 
 
More recently, other authors have questioned the two type model and developed other 
mechanistic theories. Clark and Butler (2009) proposed a three-step mechanism with a 
positive feed-back loop. Because of the inability to cough or swallow secretions pooled, 
leading to a partial airway obstruction resulting in further production of secretions.  Manthous 
(2013) considered death rattle to be secondary to dysphagia. He proposed two types of 
patients: “gurglers” and “non-gurglers”, distinguished by listening with a stethoscope over 
the glottis for gurgling sounds. This method was originally used to predict risk for hospital-
acquired pneumonia (Vazquez et al., 2010), although no study was performed that validated 
this theory for death rattle. Whilst evidence is lacking for any particular typology, dysphagia 
is an undisputed clinical sign of the dying process and is predictive of impending death (Hui 
et al., 2014; Kehl & Kowalkowski, 2013). However, whether it causes or is associated with 
death rattle remains unknown. 
 
Research into treatment for death rattle tends to focus on pharmacological remedies, but 
evidence for their efficacy remains equivocal. As death rattle can be distressing for relatives 
and clinicians alike (Kassam, Koslov, & Mendes, 2009; B. L. Wee et al., 2006a; B. L. Wee, 
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Coleman, Hillier, & Holgate, 2006b, 2008), preventing death rattle from happening in the 
first place would appear to be the best course of action. If risk factors could be identified then 
‘at risk’ patients could either be selected for prophylactic treatment or at least closely 
monitored for early intervention where possible (Sheehan et al., 2011). A comprehensive 
review of the literature is therefore required to systematically examine evidence for 
treatments for death rattle and risk factors associated with death rattle.  
 
THE REVIEW 
Aim 
The aim of the systematic review and narrative summary was to identify treatments for death 
rattle and risk factors associated with death rattle. The review questions were: 
1. What treatments are effective for death rattle? 
2. What risk factors are associated with death rattle? 
 
Design 
Quantitative systematic review and narrative summary following Cochrane Collaboration 
guidelines. 
 
Search methods 
Electronic databases that cover nursing and medical subject areas were used for the search for 
literature pertaining to respiratory tract secretions in dying people coming to the end of life. 
CINAHL, MEDLINE, Health Source Nursing and Web of Science were selected.  
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Inclusion and exclusion criteria 
Peer reviewed academic journal articles reporting original research about death rattle in 
human adults published between 1993 - 2016 were included. No restriction was put on 
language. Secondary sources like literature reviews and review articles, comments, expert 
opinions, clinical guidelines, case reports, letters and conference posters were excluded. 
Articles pertaining to children and infants were excluded as adult and paediatric palliative 
care differ in practice (Baba & Hain, 2012).  
 
Database search terms 
A basic search with the term “death rattle” in CINAHL revealed that authors used an array of 
labels for this symptom. Therefore, the advanced search had to encompass this variability. 
The following search terms were used in CINAHL, Health Source Nursing and Web of 
Science: 
(death rattle OR respiratory secretions OR bronchial secretions OR noisy breathing 
OR pulmonary rattles OR terminal respiratory secretions OR respiratory sounds) 
AND (palliative care OR terminal care OR end of life). 
 
MEDLINE search algorithm and a list of other terms are in supplementary file.  
 
Additional literature 
Leading authors in the field of death rattle research were contacted to find out whether there 
were any unpublished works or ongoing research. Those who responded did not have any 
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knowledge of ongoing or unpublished research. During the search, secondary literature was 
scrutinised, to discover primary research literature not retrieved through the database search 
(Polit & Beck, 2012). Through the hand-searching of secondary source reference lists one 
further primary research article was obtained. The full text of one randomised control trial 
could not be retrieved from any database, but was kindly provided by the authors (Likar et 
al., 2002). 
 
Search outcome 
The PRISMA diagram chart in Figure 1 details the stepwise elimination strategy that was 
employed to identify relevant literature. From the original 507 papers identified, 190 
remained after removal of duplicates. Sixty-two papers were selected following title 
screening, of which 37 were primary research reports. Subsequently, nine papers were 
excluded as they did not pertain to the research questions, but focused on perceptions and 
distress of people witnessing death rattle. Twenty-eight articles were included in the review, 
five randomised controlled trials and twenty three other studies. 
 
Quality appraisal 
Randomised controlled trials were assessed for quality using the Cochrane Collaboration’s 
Risk of Bias Tool (Higgins, 2017) following the method previously used by Wee and Hillier 
(2008) in their Cochrane review ‘Interventions for noisy breathing in patients near to death’. 
The Cochrane Collaboration’s Risk of Bias Tool considers risk in relation to selection, 
reporting, incomplete outcome data and blinding. To check for consistency of judgement two 
authors (HK and ES) assessed the one new RCT conducted since 2008.  
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For non-randomised studies the Cochrane Collaboration currently recommend ROBINS-I 
tool as developed by Sterne et al., (2016). The ROBINS-I was developed to address the 
problems of interpretation associated the Downs and Black instrument (Downs & Black, 
1998) and the Newcastle-Ottawa Scale (Wells et al., 2013). These tools were Cochrane 
Collaboration’s preferred tools, but suffered from difficulties of consistency of interpretation 
in relation to external validity (Sterne et al., 2016). The ROBINS-I starts from the perspective 
that each study is a pragmatic trial and uses a series of signalling questions to assess the risk 
of bias pre-intervention (eg, selection bias), during intervention (allocation deviation) and 
post-intervention (reporting bias). An overall judgement of bias is recorded as low, moderate, 
serious or critical. Critically biased studies are excluded from review. One author (AS) 
assessed all the included studies, whilst the two other authors (HK & ES) assessed half each. 
There was good agreement between the reviewers (K=0.72, p < 0.001) (Carpentier et al., 
2017).  
 
Data abstraction 
Using PICO methodology (Higgins, 2017) the population (country, clinical setting and 
sample size), intervention(s), comparator(s) and outcomes of the treatments for death rattle 
were abstracted from each article. PICO data were recorded in tables consistent with the 
study designs and key findings and discussion points related to the research questions were 
summarised. A Harvest plot was created to visualise the findings of all the studies included in 
this review and GRADE criteria were applied to categorise the level of confidence pertaining 
to each body of evidence where results were consistent (Figure 2). Where different studies 
came to contrary conclusions on the same topic, GRADE criteria were not applicable. All 
data were extracted by HK and AS and double checked by ES. 
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Synthesis 
This process was undertaken concurrently with the abstraction using the quality appraisal for 
risk of bias discussed above. For the RCTs, summary data were created following the style of 
used by Wee and Hillier (2008) in their systematic review of death rattle (Table 1). For the 
non-randomised studies the key data are illustrated in Table 2. As discussed above, because 
these studies were methodologically and conceptually heterogeneous, a Harvest plot was 
constructed to visualise the whole (Figure 2). 
  
 
 
RESULTS 
A total of 28 articles were included in the review: 
• five randomised control trials, 
• nine prospective studies and 
• fourteen retrospective medical records reviews. 
 
The narrative summary regarding treatments for death rattle and risk factors associated with 
death rattle is presented next. 
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What treatments are effective? 
Pharmacological treatments 
Twelve studies focused on the effectiveness of various antimuscarinic drugs or reported on 
antimuscarinic drug comparison trials. In all these studies presence of death rattle was an 
entry criterion. None examined prophylactic treatment, even though treatment with 
antimuscarinic drugs was not expected to remove existing secretions, but prevent new 
secretions from developing (Hughes et al., 2000, Back et al., 2001, Kåss & Ellershaw, 2003, 
Clark et al., 2008).  
 
Despite this knowledge, the entry criterion for all these trials was audible death rattle. An 
exclusion criterion was the simultaneous administration of antimuscarinic drugs for other 
conditions (Likar et al., 2002, 2008, Heisler et al., 2013, Protus et al., 2013). These studies 
reported that immediate effectiveness of treatments ranged from 27-86.4%, delayed effect 
from 33-76% and no effect from 22-58%. The wide range of effectiveness may be due to a 
lack of an established system regarding inclusion criteria and difficulties in measuring 
outcomes objectively and consistently. 
 
In trials where several drugs were compared, no significant difference in effectiveness 
emerged (Hughes et al., 2000, Kåss & Ellershaw, 2003, Wildiers et al., 2009). The trials 
comparing an antimuscarinic drug to placebo balanced each other out. Likar et al., (2008) 
found in favour of the intervention and Heisler et al., (2013) found in favour of placebo, 
though neither results were statistically significant (figure 2). Further, Hugel et al (2006) 
found glycopyrrolate superior to hyoscine, whereas Back et al (2001) found the opposite. The 
trustworthiness of this body of evidence is moderate to very low and therefore in summary 
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the evidence for pharmacological treatment of DR onve established is equivocal at present. 
 
Non-pharmacological management 
In palliative care there are non-pharmacological interventions for the management of death 
rattle, for example, repositioning of the patient and oropharyngeal suctioning (Twomey & 
Dowling, 2013). Although many primary research studies listed repositioning for postural 
drainage as part of caring for patients with death rattle, only Bennett (1996) went into more 
detail. In this research report it was acknowledged that the patient's position might contribute 
to the pooling of secretions, while it was later suggested that repositioning the patient from a 
supine to a lateral or upright position might improve symptoms (Bennett et al., 2002). There 
was no research found regarding repositioning or suctioning in the retrieved articles. 
 
What risk factors are associated with death rattle? 
Fourteen studies were concerned with risk factors associated with developing death rattle, 
either as their main objective or as supplementary investigations of cohort characteristics. All 
the studies were biased to a significant degree (Table 2) and so all the putative risk factors 
need further investigation. The most common risk factors are discussed below. 
 
Hydration and fluid retention symptoms 
There is considerable anecdotal evidence that high hydration levels cause patients to be 
susceptible to death rattle (Morita et al., 2004b, Plonk & Arnold, 2005). However, the 
majority of studies designed to test this hypothesis found no relationship between hydration 
levels and the development of death rattle (Ellershaw et al., 1995, Morita et al., 2005, 
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Sheehan et al., 2011, Yamaguchi et al., 2012). Only one study investigating the influence of 
hydration on end-of-life symptoms when patients were artificially hydrated with more than 
one litre per day found death rattle scores significantly increased (Nakajima et al., 2013). 
Peripheral oedema, ascites and pleural effusion and their relationship with death rattle were 
investigated in two research studies and no relationships were found (Morita et al., 2004b, 
2005). 
 
Diagnosis, dysphagia and loss of swallow and cough reflex 
Patients with cerebral malignancies were identified to be at greater risk of developing death 
rattle in two studies (Bennett, 1996; Morita et al., 2000). Patients with cerebral malignancies 
may lose their cough and swallowing reflexes and the subsequent dysphagia could be the 
determinant of death rattle (Bennett, 1996, Wildiers & Menten, 2002, Morita et al., 2004b). A 
study that entirely comprised patients with cerebral tumours, reported the lowest death rattle 
prevalence of all reviewed studies (12%) (Pace et al., 2009). However, given there was no 
comparison in this study and it was not focused on analysing death rattle, there appears to be 
reasonable if low quality evidence that cerebral malignancy appears to convey greater risk of 
developing death rattle. 
 
Pulmonary pathology was also associated with death rattle in four studies (Ellershaw et al., 
1995, Morita et al., 2000, Kåss & Ellershaw, 2003, Morita et al., 2004b). Sheehan et al., 
(2011), by contrast, could not find any association with primary diagnoses. Nevertheless the 
weight of evidence seems to favour pulmonary pathology as a likely risk factor for the 
development of death rattle. 
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Sex and age 
Four studies reported that sex and age were not statistically associated with death rattle 
(Morita et al., 2000; Sheehan et al., 2011; Wildiers & Menten, 2002). One study described 
that men had a greater risk than women conceding, however, that smoking habits and lung 
malignancies might be the causal explanation (Kåss & Ellershaw, 2003). Another study found 
women at greater risk of developing more severe death rattle symptoms (Likar et al.,2016). 
The evidence on gender and age therefore remains equivocal.  
 
Consciousness level 
Several studies proposed that impaired consciousness levels might contribute to the 
development of death rattle (Bennett, 1996; Clark et al., 2008; Pace et al., 2009). Reduced 
consciousness leads to a reduction of cough and swallow reflexes which in turn could cause 
the accumulation of secretions in the airways. Despite this plausible hypothesis, none of the 
studies demonstrated causality. Decreased consciousness levels have been found to be a 
highly specific sign of impending death in cancer patients (Hui et al., 2014), but the only 
study investigating consciousness levels and death rattle could not find any association 
(Morita et al., 2000). One study found a statistically significant relationship between 
prevalence of death rattle and disorientation to place, time and/or person (Jakobsson, et al., 
2008), suggesting further study of this area would be worthwhile.  
 
Infection 
Authors who support the classification of type 2 death rattle being infection related (eg 
Bennett, 1996, Wildiers & Menten, 2002) recommend that researchers monitor for 
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pneumonia in future studies (Kåss & Ellershaw, 2003). Airway infection was identified as a 
risk factor by Morita et al. (2000) who subsequently showed that patients with pneumonia 
were twice as likely to develop death rattle as patients without infections (Morita et al., 
2004b). More work is needed in this area 
 
Length of stay and prolonged dying phase 
Bennett (1996) showed that patients with longer admissions to in-patient settings were more 
likely to develop death rattle, while there was no significant association in another study 
(Morita et al., 2000). Prolonged dying phase, defined as the hours or days of impending 
death, was reported to be a significant risk factor by Kåss & Ellershaw (2003). 
 
Anticholinergic load 
Many drugs administered to patients have an anticholinergic effect. Agar et al. (2009) found 
the anticholinergic load of palliative patients increased over time, especially at the end of life. 
However, higher anticholinergic load did not protect the patients from death rattle as 
anticipated, but increased the likelihood of being treated for it (Sheehan et al., 2011). Given 
anticholinergic (antimuscarinic) medication is used as the primary treatment for death rattle, 
the unexpected finding that high anticholinergic load should be predictive as opposed to 
protective of death rattle warrants further investigation. 
 
DISCUSSION 
This systematic review was conducted to gain a comprehensive overview of the current 
knowledge regarding treatments for death rattle and risk factors associated with death rattle. 
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There were very few high quality studies, possibly because of the sensitive nature of the 
study focus and the challenges inherent in palliative care research. It is well known that 
recruitment problems, attrition, access and gatekeeping are enduring barriers to palliative care 
research (Jordhøy et al., 1999; Snowden & Young, 2017). 
 
Different studies used different assessment tools to measure the severity of death rattle. This 
made study comparisons difficult. Further, the studies that reported on the pharmacological 
management of death rattle all used very different treatment regimens regarding doses, 
administration methods and timing of administration (see table 3). This heterogeneity was 
why Wee and Hillier (2008) could not perform a meta-analysis in their Cochrane review. A 
decade later this remains the case. No drug regimen was found to be consistently superior to 
another and none was superior to placebo. This suggests that death rattle may be largely 
untreatable once established (Wildiers et al., 2009, Hirsch et al., 2012, Lokker et al., 2014). 
However, there have been no trials designed to manage death rattle prophylactically. Given 
that some studies have seen an improvement in the symptom burden (Back et al., 2001, 
Wildiers & Menten, 2002), a more optimistic conclusion is that antimuscarinic medication 
may yet help, but treatment needs to be prophylactic (Mercadante, 2014). Such a study would 
need a clear understanding of who may benefit from prophylaxis as prerequisite.  
 
Unfortunately, there was no conclusive evidence that any of the potential risk factors, 
investigated in the studies appraised here, predicted death rattle development. Although many 
risk factors were examined, results were generally contradictory or the evidence was weak. 
The strongest evidence was for pulmonary pathology or brain metastases. Further 
examination of these candidates would make sense, as would well designed studies 
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constructed to examine other suspected risk factors such as cholinergic load or other 
iatrogenic harm.  
 
Finally, the role and benefit of nursing interventions such as suctioning and repositioning 
need further investigation (Ahmedzai et al., 2015), as it remains unclear whether they 
contribute to the relief of the symptom (Bennett, 1996) or to the distress of the patient 
(Morita et al., 2004a). There remains no clear evidence that death rattle distresses the patient. 
Until that evidence emerges researchers should urgently focus on developing the best 
evidence to support prophylaxis, drug and non-pharmacological interventions.  
 
Limitations 
An attempt was made to include all international literature pertaining to death rattle by not 
actuating any language restrictions. Two articles published in German were included. 
However, the databases selected mainly record English language publications which may 
have unintentionally excluded relevant literature. The authors would appreciate it if missing 
articles were brought to their attention. 
 
The main limitation was the heterogeneity of the evidence. As well as the wide variety of 
study types and variability of pharmacological treatment regimes, death rattle was not 
measured consistently. In prospective studies noise intensity was most frequently assessed 
using the Victoria Respiratory Congestion Scale (Victoria Hospice Society, 2006; Back et al., 
2001; Morita et al., 2004b; Morita et al., 2005; Wildiers et al., 2009; Yamaguchi et al., 2012; 
Nakajima et al., 2013; Heisler et al., 2013). This tool is typically referred to as “Back's scale” 
after the first group to use it in 2001 for noise level assessment of death rattle (Back et al., 
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2001). In other publications the researchers used their own 3 or 5-point scales for noise levels 
(Hughes et al., 2000; Likar et al., 2002, 2008) or 4-point scales for treatment effectiveness 
(Hugel et al., 2006).  
 
Some studies used Yes/No assessments (Bennett, 1996, Morita et al., 2000, Wildiers & 
Menten, 2002). This was especially evident in medical record reviews where only the 
presence or absence of death rattle could be assessed in retrospect but not the noise intensity, 
as this was not commonly documented. In four retrospective record reviews an integrated 
care pathway for end-of-life care (ELCP) was used as a tool to assess symptoms (Ellershaw 
et al., 2001, Fowell et al., 2002, Kåss & Ellershaw, 2003). With the exception of presence or 
absence of death rattle, it will be difficult for future researchers to situate their work in this 
literature without consensus on more subtle elements of measurement. 
 
CONCLUSIONS 
Death rattle remains difficult to manage pharmacologically and non-pharmacologically. No 
treatment is superior to placebo. Prophylactic action is a more promising project, yet all 
previous high quality trials have waited until death rattle begins before randomising patients 
to treatment or control. Surely a better plan would be to test prophylaxis, but this raises the 
ethical question of who to attempt prophylaxis on. This study has identified consistent but 
low confidence evidence that shows brain and lung pathology may increase likelihood of 
developing death rattle. This is enough evidence to warrant approaching funders to support 
sufficiently powered well controlled studies in these populations. 
 
There was otherwise no evidence that any of the other potential risk factors investigated in 
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the studies appraised here could help practice in any way. To help practice, putative risk 
factors need to be unequivocally identified and then mitigated in prospective trials as above. 
The missing link at present remains the identification of such risk factors. The authors’ next 
paper takes up this challenge. A retrospective case note review and binary logistic regression 
was used to quantify the unique contribution of a range of risk factors associated with death 
rattle. This included many of those discussed here as well as some novel variables to 
systematically examine their impact. Until it is established that death rattle is entirely 
harmless such evidence is essential to mitigate the distress it causes to families and clinicians 
around the world. 
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Table 3. Drug regimes of pharmacological treatment trials 
 
 Hyoscine 
Hydrobromide (HH) 
Glycopyrronium 
Bromide (GB) 
Hyoscine 
Butylbromide (HB) 
Octreotide 
(OCT) 
Atropine (AT) Placebo 
 
Hughes et al., 2000 
 
0.4mg SC, 30min 
intervals 
0.6mg SC+2.4mg SC/ 
24hrs 
0.6mg SC 
0.2mg SC GB 
0.4mg SC GB 
0.4mg SC GB 
 
 
0.2mg SC, 30min 
intervals 
0.4mg SC+0.6mg 
SC/24hrs 
0.4mg SC 
0.4mg SC GB 
0.4mg SC GB 
0.4mg SC GB 
 
20mg SC, 30min 
intervals 
20mg SC+20mg SC/ 
24hrs 
20mg SC 
0.2mg SC GB 
0.4mg SC GB 
0.4mg SC GB 
   
Back et al., 2001 0.4mg SC, 30min 
0.4mg SC 
(1.2mg-2.4mg SC/ 
24hrs) 
 
0.2mg SC, 30min 
0.2mg SC 
(0.8mg SC/ 24hrs) 
 
 
   
Likar et al., 2002 0.5mg SC/IV 
every 4hrs 
    Saline SC/IV 
every 4 hrs x3 
0.5mg SC/IV HH 
every 4hrs 
 
IMPACT STATEMENT 
• Death rattle is very difficult to treat once established. 
• Prophylactic treatment would be optimal. 
• Risk factors need to be understood in order to deliver prophylaxis. 
• This paper reviews research on the treatments for death rattle and risk factors 
associated with death rattle in adults. 
• Further targeted research is needed as research remains equivocal. 
 
